Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Awards

- PMLiVE

Genital herpes vaccine candidate promising in phase II

Genocea Biosciences’ GEN-003 found to reduce recurrence and transmission of the virus

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

- PMLiVE

Celebrating excellence

Recognising excellence in improving patient outcomes

- PMLiVE

Pharma could make more of its real world evidence

As the ‘cost versus value’ argument rears its head once again a new award could help pharma reaffirm the value of its medicines

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

- PMLiVE

Communiqué 2016 opens with new consultancy and charity categories

Healthcare PR and med ed awards also adds content management prize

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

- PMLiVE

French government begins investigation into fatal Biotrial study

First-in-man trial leaves one dead, five hospitalised

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links